Is IGF-1 LR3 approved for human use or legal?

No. IGF-1 LR3 has no approved therapeutic application in any human indication. It is sold and used as a research reagent only. In competitive sport, it is prohibited by WADA under category S2 (Peptide Hormones, Growth Factors) both in- and out-of-competition. All human use occurs outside regulatory frameworks.

How does IGF-1 LR3 differ from native IGF-1?

IGF-1 LR3 carries a 13-amino acid N-terminal extension and an Arg3 substitution that reduce IGF-binding protein (IGFBP) affinity by approximately 1,000-fold. This dramatically increases the free, bioactive fraction in circulation and extends the half-life from under 10 minutes (free native IGF-1) to approximately 20–30 hours. It binds the same IGF-1 receptor and activates the same downstream signalling pathways.

What is the half-life and how often is it dosed anecdotally?

Approximately 20–30 hours based on animal data. Human pharmacokinetics are uncharacterised. Community protocols (anecdotal) commonly describe daily subcutaneous or intramuscular injections of 20–100 mcg, often timed post-workout, in 4–6 week cycles. These ranges are not validated in humans and should not be treated as safe or effective doses.

Does IGF-1 LR3 build muscle?

In cell culture and animal studies, IGF-1 LR3 activates PI3K/Akt/mTOR and MAPK/ERK pathways involved in protein synthesis and cell growth. Animal infusion studies confirm anabolic effects. However, no human clinical trials exist evaluating muscle mass or strength outcomes. Community reports are anecdotal only and cannot confirm efficacy or determine safe doses in humans.

Human safety data are essentially absent. Key risks include hypoglycemia (IGF-1 lowers blood glucose like insulin and impairs glucagon counterregulation, making hypoglycaemic episodes harder to self-correct), theoretical promotion of tumour growth via IGF-1R signaling, and potential visceral organ enlargement as seen in animal infusion studies. Product quality from unregulated sources is an additional real-world risk. It is not recommended for human use.

Hormonal

IGF-1 LR3

Also known as: Long R3 IGF-1, Long R3 Insulin-like Growth Factor-1, LR3-IGF-1, IGF-1 Long Arg3

A synthetic long-acting IGF-1 analogue widely used as a cell culture reagent; studied in animal models for anabolic, anti-catabolic, and tissue-growth effects. No approved...

Last updated July 11, 2026

Buy IGF-1 LR3

Overview

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analogue of human IGF-1 that differs from the native hormone in two ways: a 13-amino acid N-terminal extension and an arginine (Arg) substitution at position 3 in place of the native glutamic acid. These modifications dramatically reduce affinity for IGF-binding proteins (IGFBPs) — by at least three orders of magnitude relative to native IGF-1 — and extend the in vivo half-life from under 10 minutes (for free IGF-1) to approximately 20–30 hours. The reduced IGFBP binding means a far greater proportion of administered IGF-1 LR3 remains in free, bioactive form. In research and biotechnology settings, IGF-1 LR3 is a well-established cell culture reagent widely used to support the growth of CHO, HEK293, and other mammalian cell lines in serum-free media, where it can replace insulin at concentrations roughly 200-fold lower. It signals through the same IGF-1 receptor (IGF-1R) as native IGF-1, activating the PI3K/Akt/mTOR and MAPK/ERK pathways that drive protein synthesis, cell survival, and proliferation. IGF-1 LR3 has no approved therapeutic application in humans. It is not an approved drug anywhere in the world. In competitive sport it is prohibited under WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), both in- and out-of-competition. It appears in performance and bodybuilding communities anecdotally as an agent believed to enhance muscle hypertrophy, but no human clinical trials have evaluated it for this or any other therapeutic purpose in humans. All human use occurs outside any regulatory framework, without validated safety or efficacy data, and carries meaningful risks including hypoglycemia and theoretically tumour promotion via IGF-1R. This entry covers what is established in the peer-reviewed scientific literature and is for research reference only.

How it works

IGF-1 LR3 binds and activates the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor expressed on most human cell types. Upon binding, IGF-1R autophosphorylates and recruits insulin receptor substrate (IRS-1) and Shc adaptor proteins, branching into two major downstream arms: 1. PI3K-Akt-mTOR pathway: drives protein synthesis via p70S6K and 4EBP1 phosphorylation, inhibits FOXO-mediated muscle atrophy gene expression, and promotes glucose uptake — the primary anabolic and anti-catabolic arm. 2. MAPK/ERK pathway: drives cellular proliferation and differentiation. The N-terminal extension and Arg3 substitution of IGF-1 LR3 reduce IGFBP affinity by at least ~1,000-fold, abolishing the binding-protein buffer that normally limits free IGF-1 bioavailability in vivo. The consequence is a ~20–30 hour half-life (versus under 10 minutes for free native IGF-1 and 16–24 hours only for IGF-1 bound in ternary IGFBP complex), with a far higher fraction freely available to activate IGF-1R at peripheral tissues. These mechanisms are well characterised in cell culture and animal models; human pharmacodynamics have not been formally studied.

Researched effects

Preclinical Stimulates skeletal muscle cell protein synthesis and hypertrophy via PI3K/Akt/mTOR and MAPK/ERK signaling
Preclinical Promotes visceral organ growth (gut, kidney, adrenal, spleen) and systemic anabolic effects in animal infusion models
Preclinical Supports mammalian cell (CHO, HEK293) proliferation and survival in serum-free cell culture at low concentrations
Preclinical Reduces muscle protein catabolism and supports lean mass in GH-deficient or injured animal models
Anecdotal Increases muscle mass and strength with resistance training
Anecdotal Accelerates recovery from training and reduces muscle soreness

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established or approved clinical dosing in humans. IGF-1 LR3 has not been studied in human clinical trials for any therapeutic indication. The human pharmacokinetics, minimum effective dose, maximum tolerated dose, and safety profile in humans have not been formally characterised. There is no reference dose from regulatory agencies for any human application.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community sources (bodybuilding forums, research peptide communities) most commonly describe subcutaneous or intramuscular injections of 20–100 mcg per day, typically administered post-workout, in cycles of 4–6 weeks followed by a break. Some protocols describe split doses. Reported dosing logic — post-workout timing to coincide with anabolic windows — is not validated in any human study. These figures are drawn from community observation only and cannot be considered safe or effective doses.

Half-life: Approximately 20–30 hours in animal studies, compared to under 10 minutes for free native IGF-1 in serum. The extended half-life results from the near-elimination of IGFBP binding — native IGF-1 is largely sequestered in IGFBP binary complexes (~30–90 min half-life) and ALS ternary complexes (~16–24 hours), which provide a buffer pool; IGF-1 LR3 bypasses these and circulates as freely bioactive peptide with a distinct clearance profile. Human pharmacokinetics have not been formally established.
Routes: subcutaneous, intramuscular

Safety & side effects

Significant safety concerns exist and no long-term human safety data are available. Key risks include: Hypoglycemia: IGF-1 stimulates peripheral glucose uptake and suppresses hepatic glucose production through mechanisms similar to insulin. A human study (Kerr et al., JCI 1993) demonstrated that IGF-1 infusion lowered blood glucose and, critically, abolished the normal glucagon counterregulatory response — impairing the body's ability to self-correct during hypoglycaemic episodes. This risk is likely amplified with the extended half-life and high free-fraction of IGF-1 LR3. Tumour promotion (theoretical): The IGF-1R signaling axis is well established as a driver of cancer cell proliferation and survival, and elevated circulating IGF-1 correlates with increased cancer incidence. IGF-1R overexpression drives PI3K/Akt and MAPK/ERK-mediated tumour resistance. Prolonged supraphysiological IGF-1R stimulation from exogenous IGF-1 LR3 is theoretically mitogenic; this risk has not been studied in the context of bodybuilding-range dosing. Organ enlargement: Animal infusion studies have documented significant growth of visceral organs (adrenals, gut, kidneys, spleen); long-term implications in humans are unstudied. Product quality: Research-grade peptides are unregulated; impurity, mislabeling, and sterility risks are real. IGF-1 LR3 is not an approved drug in any jurisdiction. It is banned in competitive sport by WADA (S2) both in- and out-of-competition. All human use occurs without regulatory oversight. This is for research reference only; it is not a recommendation for human use.

Research summary

The evidence base for IGF-1 LR3 is substantial in cell biology and animal models but entirely absent in human clinical trials. Its role as a cell culture reagent is well established: it supports serum-free mammalian cell growth at concentrations orders of magnitude lower than insulin, making it a standard bioproduction tool. In animal studies, infusion of IGF-1 LR3 produces significant visceral organ hypertrophy and anabolic effects at peripheral tissues, consistent with its high potency and prolonged bioavailability from IGFBP resistance. The mechanistic rationale for muscle anabolic effects is solid at the receptor-signalling level: IGF-1R agonism driving PI3K/Akt/mTOR (protein synthesis) and MAPK/ERK (cell proliferation) is among the best-characterised growth factor signalling cascades in biology. The IGFBP resistance of IGF-1 LR3 — providing ~1,000-fold lower IGFBP affinity than native IGF-1 — is pharmacologically rational as a strategy for enhanced tissue delivery. However, the translation gap is total: no human clinical trial has evaluated IGF-1 LR3 for performance, body composition, or any therapeutic indication. WADA prohibits it under S2, and no detection method in sport was validated as of 2021. Safety signals from the broader IGF-1 literature — particularly the hypoglycemia risk (with impaired glucagon counterregulation) and the well-established role of IGF-1R signaling in cancer biology — represent meaningful, uncharacterised risks at the doses and durations used in community practice. The honest summary is that IGF-1 LR3 is a well-understood research tool with plausible anabolic mechanisms but zero human efficacy or safety data. Community claims of pronounced muscle-building effects rest entirely on anecdote and extrapolation from cell and animal biology.

FAQ

Is IGF-1 LR3 approved for human use or legal?: No. IGF-1 LR3 has no approved therapeutic application in any human indication. It is sold and used as a research reagent only. In competitive sport, it is prohibited by WADA under category S2 (Peptide Hormones, Growth Factors) both in- and out-of-competition. All human use occurs outside regulatory frameworks.
How does IGF-1 LR3 differ from native IGF-1?: IGF-1 LR3 carries a 13-amino acid N-terminal extension and an Arg3 substitution that reduce IGF-binding protein (IGFBP) affinity by approximately 1,000-fold. This dramatically increases the free, bioactive fraction in circulation and extends the half-life from under 10 minutes (free native IGF-1) to approximately 20–30 hours. It binds the same IGF-1 receptor and activates the same downstream signalling pathways.
What is the half-life and how often is it dosed anecdotally?: Approximately 20–30 hours based on animal data. Human pharmacokinetics are uncharacterised. Community protocols (anecdotal) commonly describe daily subcutaneous or intramuscular injections of 20–100 mcg, often timed post-workout, in 4–6 week cycles. These ranges are not validated in humans and should not be treated as safe or effective doses.
Does IGF-1 LR3 build muscle?: In cell culture and animal studies, IGF-1 LR3 activates PI3K/Akt/mTOR and MAPK/ERK pathways involved in protein synthesis and cell growth. Animal infusion studies confirm anabolic effects. However, no human clinical trials exist evaluating muscle mass or strength outcomes. Community reports are anecdotal only and cannot confirm efficacy or determine safe doses in humans.
Is IGF-1 LR3 safe?: Human safety data are essentially absent. Key risks include hypoglycemia (IGF-1 lowers blood glucose like insulin and impairs glucagon counterregulation, making hypoglycaemic episodes harder to self-correct), theoretical promotion of tumour growth via IGF-1R signaling, and potential visceral organ enlargement as seen in animal infusion studies. Product quality from unregulated sources is an additional real-world risk. It is not recommended for human use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.